Europe Cardiac Sarcoidosis Market, By Treatment (Diagnosis, Drugs), Drugs (Corticosteroids and Immunosuppressant Drugs), Inhibitors (Adalimumab, Infliximab and Others), Drugs Type (Branded, Generic), Route of Administration (Oral, Parenteral), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others) – Industry Trends and Forecast to 2030.
Europe Cardiac Sarcoidosis Market Analysis and Size
Sarcoidosis is a multisystem inflammatory disease with an unknown etiology. Cardiac sarcoidosis is diagnosed in approximately 2-5% of patients with another systemic sarcoidosis; however, autopsy have revealed that cardiac sarcoidosis may be as high as 20-30% in the United States. African Americans have 3.8 times the prevalence of sarcoidosis as Caucasians in the United States and Europe. The prevalence of cardiac sarcoidosis in Japanese patients may be as high as 58%, and it is the cause of death in 85% of sarcoid patients in Japan. Cardiovascular sarcoidosis has a poor prognosis and patients can quickly deteriorate.
Data Bridge Market Research analyses that the cardiac sarcoidosis market which was USD 22669.05 million in 2022, is expected to reach USD 65120.61 million by 2030, at a CAGR of 14.1% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Cardiac Sarcoidosis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Diagnosis, Drugs), Drugs (Corticosteroids and Immunosuppressant Drugs), Inhibitors [Adalimumab, Infliximab and Others], Drugs Type (Branded, Generic), Route of Administration (Oral, Parenteral), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Mallinckrodt (U.K.), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), Relief Therapeutics (Switzerland), Sandoz International GmbH (Switzerland), Teva Pharmaceuticals USA, INC. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), sanofi-aventis U.S. LLC (U.S.), Zydus Pharmaceuticals, Inc. (U.S.), Fresenius Kabi USA (U.S.), Merck & Co., Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Cardiac sarcoidosis is a rare inflammatory condition in which immune cells form granulomas in various areas of the heart, causing problems ranging from arrhythmia to heart failure. The causes of cardiac sarcoidosis are unknown at this time. An immune system overreaction may cause the disease to an infectious agent (such as bacteria or viruses), chemical, or allergen.
Europe Cardiac Sarcoidosis Market Dynamics
Drivers
- Rise in cardiovascular disease
There is also an increase in the prevalence of obesity among adults and youth, which is one of the leading causes of cardiovascular disease, boosting market growth. As the prevalence of cardiovascular diseases rises, so does public awareness of health, prompting people to seek out simpler and more accessible diagnostics and treatment methods, such as easy-to-use cardiac monitoring devices. As a result, the market is expected to grow rapidly due to an increase in cardiovascular diseases during the forecast period.
- Enhanced demand of cardiac sarcoidosis drugs and diagnosis
Corticosteroid treatment may slow the progression of cardiac disease and improve survival, but it does not appear to reduce the frequency of ventricular arrhythmias. 16 Steroids' mechanism of action in cardiac sarcoidosis is unknown, but it is thought that these agents can slow the progression of inflammation and fibrosis by re-establishing a normal TH1/TH2 balance. w32 Prednisone doses of 60-80 mg per day are commonly prescribed at first. In one study, a starting dose of 30 mg/day was found to be adequate for improving prognosis. These are the certain factors for the enhancement of cardiac sarcoidosis diagnosis.
Opportunities
- Development of new and advanced cardiac sarcoidosis drugs
Gallium67 scintigraphy Gallium67 scintigraphy is also used to diagnose myocardial involvement in sarcoidosis. Gallium67 accumulates only in areas of active inflammation, so the test is only positive when the disease is active. Okayama and colleagues reported that when thallium showed myocardial defects, gallium heart uptake did not add more diagnostic information but was predictive of the efficacy of corticosteroid treatment.
Gallium single photon emission computed tomography (SPECT) scanning is frequently difficult to visualise abnormal nuclide uptake into the myocardium, because of the inability to distinguish gallium uptake in other organs from that in the myocardium. Nakazawa and colleagues recently reported that dual SPECT using gallium67 and technetium99m can significantly improve the accuracy and spatial resolution of gallium67 SPECT scanning in the diagnosis of cardiac sarcoidosis.
Restraints/Challenges
- Complications of Antiarrhythmic treatment
Antiarrhythmic therapy and blockers are frequently required in the treatment of sarcoid heart disease. There have been no prospective studies evaluating the use of these agents in cardiac sarcoidosis patients. Blockers may increase the risk of heart block, and amiodarone may worsen restrictive lung disease in sarcoidosis. As a result, the doctor must carefully weigh the benefits and risks of prescribing these medications.
This cardiac sarcoidosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiac sarcoidosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In April 2020, Mallinckrodt sponsored an awareness programme launched by the American Lung Association (ALA) and the Foundation for Sarcoidosis Research (FSR) to empower sarcoidosis patients to fight against such a chronic disease and follow some measures to protect themselves from cardiac sarcoidosis. The launch of this awareness campaign aided the company in raising its public profile.
- In July 2019, Hikma Pharmaceuticals PLC and Civica entered into a five-year agreement to reduce the generic drug shortage in the United States. Most drugs used to treat cardiac sarcoidosis, including methotrexate, are available as generic drugs. This agreement enabled the company to maintain a continuous drug supply, allowing it to invest significantly in expanding its manufacturing capabilities.
Europe Cardiac Sarcoidosis Market Scope
The cardiac sarcoidosis market is segmented on the basis of treatment, drugs type, inhibitors, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Diagnosis
- CT Scan
- PET
- ECG
- Others
- Drugs
- Methotrexate
- Corticosteroids
- Immunosuppressant Drugs
- Mycophenolate Mofetil
- Azathioprine
- Leflunomide
- Cyclophosphamide
- Others
- Antiarrhythmic Drugs
- Antimalarial Drugs
- Chloroquine
- Hydroxychloroquine
- Tumor Necrosis Factor-Alpha (Tnf-Alpha)
Inhibitors
- Adalimumab
- Infliximab
- Others
Drugs Type
- Branded and Generic
- H.P. Acthar Gel
- Adempas
- Rayos
- Ofev
- Ara 290
- Others
Route of Administration
- Oral and Parenteral
- Intravenous
- Subcutaneous
- Others
End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Cardiac Sarcoidosis Market Regional Analysis/Insights
The cardiac sarcoidosis market is analyzed and market size insights and trends are provided by country, treatment, drugs type, inhibitors, route of administration, end user and distribution channel as referenced above.
The countries covered in the cardiac sarcoidosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Germany is dominating the Europe cardiac sarcoidosis market with a large number of companies operating in the market with high focus on research and innovation and API manufacturing. Furthermore, pharmaceutical industry investment has increased significantly in recent years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The cardiac sarcoidosis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cardiac sarcoidosis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cardiac sarcoidosis market. The data is available for historic period 2011-2021.
Competitive Landscape and Cardiac Sarcoidosis Market Share Analysis
The cardiac sarcoidosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cardiac sarcoidosis market.
Some of the major players operating in the cardiac sarcoidosis market are:
- Hikma Pharmaceuticals PLC (U.K.)
- Mylan N.V. (U.S.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Mallinckrodt (U.K.)
- AbbVie Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Relief Therapeutics (Switzerland)
- Sandoz International GmbH (Switzerland)
- Teva Pharmaceuticals USA, INC. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- sanofi-aventis U.S. LLC (U.S.)
- Zydus Pharmaceuticals, Inc. (U.S.)
- Fresenius Kabi USA (U.S.)
- Merck & Co., Inc. (U.S.)
Research Methodology: Europe Cardiac Sarcoidosis Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-